---
figid: PMC9087341__fnagi-14-838173-g001
figtitle: Exploring the Pharmacological Potential of Metformin for Neurodegenerative
  Diseases
organisms:
- Mus musculus
- Rattus norvegicus
- Drosophila melanogaster
- Caenorhabditis elegans
- Syzygium aromaticum
- Galega officinalis
- Homo sapiens
- Bos taurus
- prion
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
- Mus musculus
pmcid: PMC9087341
filename: fnagi-14-838173-g001.jpg
figlink: /pmc/articles/PMC9087341/figure/F1/
number: F1
caption: Mechanisms of metformin related to neuroprotection for NDD. The progression
  of neurodegenerative diseases has been shown to be associated with Tau phosphorylation,
  oxidative stress, amyloid protein accumulation and inflammation. Metformin can inhibit
  the NF-κB pathway, inhibit the astrocyte inflammation. In neurons, metformin directly
  inhibits Tau phosphorylation through PP2A. Most importantly, metformin inhibits
  respiratory chain complex 1, which inhibits energy production. This reduces ROS
  production, increases the AMP/ATP ratio, and then activates AMPK, which in turn
  inhibits Aβ plaque, protein synthesis, cell death and autophagy pathways. In general,
  metformin has great potential for neuroprotection based on current preclinical studies.
papertitle: Exploring the Pharmacological Potential of Metformin for Neurodegenerative
  Diseases.
reftext: Ming-Rui Du, et al. Front Aging Neurosci. 2022;14:838173.
year: '2022'
doi: 10.3389/fnagi.2022.838173
journal_title: Frontiers in Aging Neuroscience
journal_nlm_ta: Front Aging Neurosci
publisher_name: Frontiers Media S.A.
keywords: metformin | neurodegeneration | AMP-activated protein kinase | narrative
  review | pharmacology
automl_pathway: 0.9462869
figid_alias: PMC9087341__F1
figtype: Figure
redirect_from: /figures/PMC9087341__F1
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9087341__fnagi-14-838173-g001.html
  '@type': Dataset
  description: Mechanisms of metformin related to neuroprotection for NDD. The progression
    of neurodegenerative diseases has been shown to be associated with Tau phosphorylation,
    oxidative stress, amyloid protein accumulation and inflammation. Metformin can
    inhibit the NF-κB pathway, inhibit the astrocyte inflammation. In neurons, metformin
    directly inhibits Tau phosphorylation through PP2A. Most importantly, metformin
    inhibits respiratory chain complex 1, which inhibits energy production. This reduces
    ROS production, increases the AMP/ATP ratio, and then activates AMPK, which in
    turn inhibits Aβ plaque, protein synthesis, cell death and autophagy pathways.
    In general, metformin has great potential for neuroprotection based on current
    preclinical studies.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - tau
  - wrd
  - wdb
  - mts
  - tws
  - Pp2A-29B
  - A3
  - nAChRalpha3
  - Prosalpha3
  - alphaTub84D
  - SNF4Agamma
  - AMPKalpha
  - Mtor
  - Tor
  - ATPsynbeta
  - Atpalpha
  - Amph
  - Dif
  - dl
  - Rel
  - foxo
  - Atg1
  - MAPT
  - PTPA
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - MTOR
  - ATP8A2
  - APRT
  - MFAP1
  - NFKB1
  - FOXO1
  - FOXO3
  - FOXO4
  - FOXO6
  - ULK1
  - Mapt
  - Csnk1e
  - Ppp2ca
  - Ppp2r1a
  - Nfkb1
  - Ulk1
---
